TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06508099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 300 000 IU single dose orally
Study: NCT05961059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5 μg InvaplexAR-Detox
Description: 2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg InvaplexAR-Detox
Description: 10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
Study: NCT06413069

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raw whole almonds
Description: Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks. Patients of the no-nut group will receive 6,7 kgs of almonds after finishing the study, supporting their compliance as untreated group.
Study: NCT05961059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg InvaplexAR-Detox
Description: 10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.1 μg of dmLT
Description: 0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.1 μg of dmLT
Description: 0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccination with commercially available saline solution.
Study: NCT06468215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Description: Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Description: Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.
Study: NCT06508099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 100 000 IU single dose orally
Study: NCT06042127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM-F
Description: POEM-F would be performed as described in the arms section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional POEM
Description: Anterior POEM performed as described in the arms section
Study: NCT06613893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: Anesthesia will be maintained by total intravenous anesthesia with propofol infusion (4 to 12 mcg/kg/min) and fentanyl infusion (3-4.8 mcg /kg/hour)(Ting 2019) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational anesthesia
Description: Anesthesia will be maintained with inhaled isoflurane, Iso-MAC from (0.7 to 1.4%)(Hawkley, Preston, and Maani 2018) and fentanyl 0.35 to 0.5 mcg/kg supplementary dose will be given if needed to maintain the heart rate and blood pressure within the range of ±20% of the baseline
Study: NCT05670847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exogenous ketone ester
Description: 500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
Study: NCT06517823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib + Cyanocobalamin fixed dose
Description: One tablet of 90 mg / 0.50 mg a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib fixed dose
Description: One pill of 90 mg a day
Study: NCT06058078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RY_SW01 cell injection
Description: Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RY_SW01 cell injection
Description: Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Drugs for LN treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Drugs for LN treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Basic treatment
Description: Drugs for LN treatment
Study: NCT06547021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A light electrical current with zero frequency (tDCS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma Transcranial Alternating Current Stimulation (tACS)
Description: A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks.
Study: NCT06501872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physician-modified aortic endograft
Description: Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
Study: NCT06547021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Transcranial Alternating Current Stimulation (tACS)
Description: A light electrical current with personalized theta frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham stimulation (i.e. only slight stimulation at the beginning and at the end for a few seconds with majority of the time having no stimulation) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks.
Study: NCT06681415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution
Description: Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion.
Study: NCT06681597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry ketone
Description: Human consumed 500mg of raspberry ketone

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry ketone
Description: Human consumed 500mg of raspberry ketone
Study: NCT05249790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recommended treatment schedule
Description: Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Treatment regimens different from the recommended one according to family physician personal practice
Study: NCT06238362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPAP
Description: Algorithm for modification of CPAP therapy where pressure is reduced during the inspiratory phase though much of the expiratory phase, then is returned to full pressure near the end of the expiratory phase. Note that the same device that delivers CPAP can also deliver TPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Gold standard for treating sleep apnea.
Study: NCT06679790

Intervention type: OTHER
Intervention: None interventional
Description: Observational study
Study: NCT06680947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 610
Description: Subcutaneously injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 610
Description: Subcutaneously injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously injection.
Study: NCT05360966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-15512 Ophthalmic Solution
Description: Topical ocular administration of one drop in both eyes BID for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Study: NCT03672760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioBreathApp
Description: Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IMT PowerBreath
Description: Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IMT PowerBreath Placebo
Description: Inspiratory Muscle Training (IMT) without load
Study: NCT05160025

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual reality bicycling
Description: This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
Study: NCT03269396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Larynx Allograft Transplantation
Description: This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
Study: NCT06619080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block with bupivacaine and corticosteroids
Description: - GROUP 1:Genicular Nerve Block with Bupivacaine and Corticosteroids: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block with bupivacaine
Description: - GROUP 2: Genicular Nerve Block with Bupivacaine: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Genicular nerve block with saline
Description: - GROUP 3: Genicular Nerve Block with Saline: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects.
Study: NCT06692686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthoses (AFOs)
Description: Participants will wear each of the three AFO treatment options (custom-fit, custom fabricated-solid ankle, and custom fabricated-articulating) over three separate four-week periods. During each four-week period, individuals will also receive up to four AFO training sessions to ensure optimized functionality. Through the course of the entire real-world use period, orthotists will provide any care and adjustments needed consistent with routine clinical practice. Within one week of completing the four-week period, the participants will return to their clinic or gait lab for study assessments.
Study: NCT06241456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as an IV infusion at planned dose levels.
Study: NCT06630143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Virtual and Clinical Simulation
Description: Participants will complete a preeclampsia case scenario through virtual simulation first and then engage in a clinical simulation involving the same case. This sequential intervention is designed to reinforce knowledge and skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual simulation
Description: Participants will complete the preeclampsia case scenario using the vSim® platform, allowing them to engage in virtual clinical decision-making.
Study: NCT06241456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as an IV infusion at planned dose levels.
Study: NCT06680245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: Patients needing Ahmed valve implants to control intraocular pressures will be eligible. Eligible patients who consent will be randomized to receive either mitomycin-C or no intervention during implant surgery. Screening visits occur one week before surgery to assess eligibility and take baseline measurements (visual acuity, IOP, anterior chamber reaction). On surgery day, patients register at SJHH King Campus and undergo randomization. IOP is measured using a tonopen in the OR. An experienced glaucoma specialist performs the surgery, injecting 0.2 mg/ml mitomycin-C into the sclera for the experimental group, while the control group receives no intervention. The area is irrigated with 40mL balanced salt solution before implant insertion. Post-operative care includes topical antibiotics and steroids for six weeks, with follow-ups at 1 and 2 weeks, and 1, 3, 6, and 12 months to monitor visual acuity, IOP, anterior chamber reaction, complications, and additional glaucoma medications.
Study: NCT04840147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JointRep®
Description: JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microfracture
Description: Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
Study: NCT06701682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A: vilobelimab
Description: Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort A: placebo
Description: Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
Study: NCT06699342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation with Left bundle branch area pacing (LBBAP)
Description: Left bundle branch pacing is a novel pacing modality that can bypass the pathological or disease-vulnerable region in the cardiac conduction system, to provide physiological pacing modality for patients.~The procedure involves the implantation of a permanent pacemaker with a pacing lead positioned at the left bundle branch area to achieve physiological conduction system pacing. LBBAP-Pacemaker device and leads should be implanted according to the physician's standard practice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrioventricular node ablation (AVNA)
Description: Atrioventricular node ablation uses heat energy, called radiofrequency energy, to destroy the area between the upper and lower heart chambers. This area is called the atrioventricular node.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pharmacologic therapy optimized for Atrial Fibrillation management
Description: Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.~Treatment is tailored based on patient tolerance and clinical efficacy.
Study: NCT06701669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B: paridiprubart
Description: Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort B: placebo
Description: Administered as a single IV dose of placebo on Day 1
Study: NCT06241456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as an IV infusion at planned dose levels.
Study: NCT06707454

Intervention type: DEVICE
Intervention: Digital Electroencephalography (DEEG)
Description: The enrolled patients will undergo Digital Electroencephalography (DEEG) monitoring for at least two hours. A senior epileptologist will make a DEEG interpretation to detect DEEG abnormality. DEEG patterns will be categorized according to the American Clinical Neurophysiology Society's standardized critical care DEEG terminology(normal, slowing and asymmetry, sharp and wave, periodic discharges, ictal patterns burst suppression, and electrocerebral silence)
Study: NCT06707844

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment will include:~* Stretching exercises (5Reps with 15sec hold): Gastrocnemius-soleus stretch, TA stretch.~* Strengthening exercises (5Sets, 5Reps, 5sec hold): Weight-bearing lunges, Short-foot exercise.~* Maitland mobilization Grade 2 \& 3 (3 Sets, 20Reps) at Talonavicular joint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment will include:~* Stretching exercises (5Reps with 15sec hold): Gastrocnemius-soleus stretch, TA stretch.~* Strengthening exercises (5Sets, 5Reps, 5sec hold): Weight-bearing lunges, Short-foot exercise.~* Maitland mobilization Grade 2 \& 3 (3 Sets, 20Reps) at Talonavicular joint.
Study: NCT06707376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Kangaroo Mother Care
Description: * Initiation of KMC within 24 hours of birth.~* Continuous skin-to-skin contact for at least 8 hours per day, with gradual increase based on infant tolerance.~* Support for exclusive breastfeeding or expressed breast milk feeding.~* Ongoing assessment and support from trained neonatal nurses and lactation consultants.
Study: NCT06709573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasopressin - early initiation
Description: BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 10-20 mcg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasopressin - standard initiation
Description: BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 20-35 mcg/min